Cargando…

Rapidly Growing Locally Advanced Non-Small Cell Lung Cancer Treated with Definitive Chemoradiotherapy Using Adaptive Volumetric Modulated Arc Therapy Followed by Durvalumab Maintenance: A Case Report

Patient: Male, 43-year-old Final Diagnosis: Lung cancer Symptoms: — Medication:— Clinical Procedure: — Specialty: Oncology • Radiology OBJECTIVE: Unusual or unexpected effect of treatment BACKGROUND: It is difficult to reduce lung toxicity in chemoradiotherapy for locally advanced lung cancer. Volum...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sakai, Keisuke, Fujii, Kota, Hanazawa, Hideki, Sakai, Mami, Tsutsumi, Yurie, Fukuda, Yasushi, Akaike, Yoko, Notohara, Kenji, Itasaka, Satoshi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	International Scientific Literature, Inc. 2022
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8815321/ https://www.ncbi.nlm.nih.gov/pubmed/35095092 http://dx.doi.org/10.12659/AJCR.934767

Ejemplares similares

Durvalumab after definitive chemoradiotherapy in locally advanced NSCLC: Data of the German EAP
por: Faehling, Martin, et al.
Publicado: (2020)

Prospective evaluation of definitive chemoradiotherapy with volumetric modulated arc therapy in patients with muscle invasive carcinoma of urinary bladder
por: Rastogi, Madhup, et al.
Publicado: (2020)

Association of volumetric-modulated arc therapy with radiation pneumonitis in thoracic esophageal cancer
por: Inoo, Hiroyuki, et al.
Publicado: (2022)

Clinicopathological analysis of a superior sulcus tumor treated by salvage surgery after concurrent definitive chemoradiotherapy followed by durvalumab: A case report
por: Funaki, Soichiro, et al.
Publicado: (2022)

Long-term complications of definitive chemoradiotherapy for esophageal cancer using the classical method
por: Ito, Hitoshi, et al.
Publicado: (2017)

Successful Treatment with Definitive Concurrent Chemoradiotherapy Followed by Durvalumab Maintenance Therapy in a Patient with Tracheal Adenoid Cystic Carcinoma
por: Mikami, Erika, et al.
Publicado: (2023)

Acceptable fetal dose using flattening filter-free volumetric arc therapy (FFF VMAT) in postoperative chemoradiotherapy of tongue cancer during pregnancy()
por: Takahashi, Wataru, et al.
Publicado: (2019)

Asthma caused by durvalumab after chemoradiotherapy in two patients with non‐small cell lung cancer
por: Uemura, Takehiro, et al.
Publicado: (2021)

Destroyed lung due to sustained inflammation after chemoradiotherapy followed by durvalumab
por: Taima, Kageaki, et al.
Publicado: (2020)

Efficacy of robust optimization plan with partial‐arc VMAT for photon volumetric‐modulated arc therapy: A phantom study
por: Miura, Hideharu, et al.
Publicado: (2017)

Effect of topical agents on skin surface dose in volumetric modulated arc therapy for head and neck cancer
por: Ueda, Hikari, et al.
Publicado: (2023)

Long-term outcome of definitive radiotherapy for cervical esophageal squamous cell carcinoma
por: Sakanaka, Katsuyuki, et al.
Publicado: (2018)

Recurrence patterns and progression-free survival after chemoradiotherapy with or without consolidation durvalumab for stage III non-small cell lung cancer
por: Kishi, Noriko, et al.
Publicado: (2022)

Hypofractionated Volumetric-Modulated Arc Radiotherapy for Patients With Non-Small-Cell Lung Cancer Not Suitable for Surgery or Conventional Chemoradiotherapy or SBRT
por: Shen, Junyue, et al.
Publicado: (2021)

Feasibility of Four-dimensional Adaptation of Volumetric Modulated Arc Therapy Based on Volumetric Modulated Arc Therapy-computed Tomography
por: Zhao, Xiaodong, et al.
Publicado: (2023)

Severe Radiation-Induced Lymphopenia Attenuates the Benefit of Durvalumab After Concurrent Chemoradiotherapy for NSCLC
por: Jing, Wang, et al.
Publicado: (2022)

Impact of Lymphopenia Recovery After Chemoradiotherapy on Durvalumab Consolidation Therapy in Stage III NSCLC
por: Kuge, Tomoki, et al.
Publicado: (2023)

Rapidly growing carcinosarcoma of the esophagus following definitive chemoradiotherapy: A case report and the literature review
por: Yamauchi, Takuro, et al.
Publicado: (2022)

Dosimetric advantages and clinical outcomes of simultaneous integrated boost intensity-modulated radiotherapy for anal squamous cell carcinoma
por: Sakanaka, Katsuyuki, et al.
Publicado: (2017)

Dual-gated volumetric modulated arc therapy
por: Fahimian, Benjamin, et al.
Publicado: (2014)

Dosimetric and delivery characterizations of full-arc and half-arc volumetric-modulated arc therapy for maxillary cancer
por: Miura, Hideharu, et al.
Publicado: (2012)

Three-dimensional radiochromic film dosimetry for volumetric modulated arc therapy using a spiral water phantom
por: Tanooka, Masao, et al.
Publicado: (2013)

Long-term outcomes of induction chemotherapy followed by chemoradiotherapy using volumetric-modulated arc therapy as an organ preservation approach in patients with stage IVA-B oropharyngeal or hypopharyngeal cancers
por: Kubo, Katsumaro, et al.
Publicado: (2020)

Long‐term response with durvalumab after chemoradiotherapy for pulmonary pleomorphic carcinoma: A case report
por: Yorozuya, Takafumi, et al.
Publicado: (2020)

Risk factor of pneumonitis on dose-volume relationship for chemoradiotherapy with durvalumab: Multi-institutional research in Japan
por: Oshiro, Yoshiko, et al.
Publicado: (2021)

Effect of durvalumab on local control after concurrent chemoradiotherapy for locally advanced non‐small cell lung cancer in comparison with chemoradiotherapy alone
por: Abe, Takanori, et al.
Publicado: (2020)

Evaluation of mixed energy partial arcs for volumetric modulated arc therapy for prostate cancer
por: Momin, Shadab, et al.
Publicado: (2019)

Treatment outcomes of definitive chemoradiotherapy for patients with hypopharyngeal cancer
por: Nakahara, Rie, et al.
Publicado: (2012)

Evaluation of volumetric modulated arc therapy for postmastectomy treatment
por: Nichols, Geoffrey P, et al.
Publicado: (2014)

Prostate volumetric‐modulated arc therapy: dosimetry and radiobiological model variation between the single‐arc and double‐arc technique
por: Chow, James C.L., et al.
Publicado: (2013)

Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC—Update from PACIFIC
por: Gray, Jhanelle E., et al.
Publicado: (2019)

The Meaning of Lymphadenopathies During Adjuvant Durvalumab After Chemoradiotherapy for Lung Cancer: Thinking Beyond Disease Progression
por: Pantarotto, Marcos, et al.
Publicado: (2022)

Exploring causes and consequences of early discontinuation of durvalumab after chemoradiotherapy for non-small cell lung cancer
por: Pennock, Michael, et al.
Publicado: (2023)

Minimal Change Disease Associated With Durvalumab
por: Toda, Masataro G., et al.
Publicado: (2021)

Initial experience with intra‐fraction motion monitoring using Calypso guided volumetric modulated arc therapy for definitive prostate cancer treatment
por: Bell, Linda J., et al.
Publicado: (2017)

Volumetric Modulated Arc Therapy Improves Outcomes in Definitive Radiochemotherapy for Anal Cancer Whilst Reducing Acute Toxicities and Increasing Treatment Compliance
por: Possiel, Jacqueline, et al.
Publicado: (2021)

Prognostic factor analysis of definitive radiotherapy using intensity-modulated radiation therapy and volumetric modulated arc therapy with boluses for scalp angiosarcomas
por: Kashihara, Tairo, et al.
Publicado: (2022)

Gafchromic EBT‐XD film: Dosimetry characterization in high‐dose, volumetric‐modulated arc therapy
por: Miura, Hideharu, et al.
Publicado: (2016)

Volumetric-Modulated Arc Therapy for Giant-Cell Tumor of Temporal Bone: An Illustrative Case Report
por: Kubo, Katsumaro, et al.
Publicado: (2022)

Acquired amegakaryocytic thrombocytopenia after durvalumab administration
por: Suyama, Takahiro, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_tmon4er92h2a62dgaddoan502p